



10 / 501071

INVESTOR IN PEOPLE

09 JUL 2004

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 21 FEB 2003

EPO PCT

PRIORITY DOCUMENT


SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 24 January 2003

BEST AVAILABLE COPY



The
Patent
Office

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Fee: £0

1. Your reference

43952/JMD/MAR

2. Patent application number
(7)

0200689.8

10 JAN 2002

14JAN02 E687618-1 D01631
P01/7700 0.00-0200689.8

3. Full name and postcode of the or of each applicant (underline all surnames)

University of Newcastle Upon Tyne
6 Kensington Terrace
Newcastle Upon Tyne
NE1 7RU

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of incorporation

UNITED KINGDOM

6594709001

4. Title of the invention

Fusion Proteins

5. Full name, address and postcode in the United Kingdom to which all correspondence relating to this form and translation should be sent

Reddie & Grose
16 Theobalds Road
LONDON
WC1X 8PL

Patents ADP number (if you know it)

91001 ✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application
(if you know it)

Date of filing
(day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

YES

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document.

Continuation sheets of this form

| | |
|-------------|-------|
| Description | 19 |
| Claim(s) | 5 |
| Abstract | 0 |
| Drawing(s) | 6 a b |

10. If you are also filing any of the following, state how many against each item.

| | |
|---|---|
| Priority documents | 0 |
| Translations of priority documents | 0 |
| Statement of inventorship and right to grant of a patent (<i>Patents Form 7/77</i>) | 0 |
| Request for preliminary examination and search (<i>Patents Form 9/77</i>) | 1 |
| Request for substantive examination (<i>Patents Form 10/77</i>) | 0 |
| Any other documents (<i>please specify</i>) | |

11.

I/We request the grant of a patent on the basis of this application.

Signature

Reddie & Grose

Date

9 January 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

S J N GOODMAN
01223 360350**Warning**

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

FUSION PROTEINS

The present invention relates to fusion proteins (fusion polypeptides), particularly for use in expression and/or purification systems.

Purified proteins are required for several applications. However, the isolation of pure proteins, in sufficient quantities, is sometimes problematic. For protein function studies, large amounts of a protein of interest (for example, a mutated protein) are often needed. Various expression systems have been used for heterologous production of proteins. *Escherichia coli* (*E. coli*) is still the most common host despite huge advances in the area of protein expression in the last ten years in other hosts. *E. coli* is popular because expressing proteins in the bacterium is relatively simple and a vast amount of knowledge about bacterium itself exists, and (sometimes most importantly) because of the low costs associated with production.

Proteins can be expressed in *E. coli* either directly or as fusions (of a "fusion partner" and a protein or polypeptide), also known as fusion proteins. The purpose of fusion partners is to provide affinity tags (e.g. His_n tag, glutathione-S-transferase, cellulose binding domain, intein tags), to make proteins more soluble (e.g. glutathione-S-transferase), to enable formation of disulphide bonds (e.g. thioredoxin), or to export fused proteins to the periplasm where conditions for the formation of disulphide bonds are more favourable (e.g. DsbA and DsbC). Proteins used as fusion partners are normally small (less than 30 kDa).

TolA is a periplasmic protein involved in (1) maintaining the integrity of the inner membrane and (2) the uptake of colicins and bacteriophages. The first function is evidenced by the increased outer membrane instability (e.g. SDS sensitivity) of TolA- mutants. The second function is based upon the use of tolA as a receptor by phage proteins (Lubkowski, J. *et al.*, 1999, *Structure With Folding & Design* 7: 711-722) and colicins (Gokce, I. *et al.*, 2000, *J. Mol. Biol.* 304: 621-632). This has been revealed both by the phage/colicin resistance of tolA mutants and by direct demonstration of the tolA -protein interactions by physical methods. TolA is composed of three domains. A short N-terminal domain is composed of a single transmembrane helix, which anchors TolA in the inner membrane. The second, largest domain

is polar and mainly α -helical. A C-terminal domain III (TolAIII) is small and composed of 92 amino acids. Its 3D structure was recently solved in a complex with N1 domain of minor coat gene 3 protein of Ff filamentous bacteriophage (Holliger, P. *et al.*, 1999, J. Mol. Biol. 288: 649-657). It is tightly folded into a slightly elongated protein with the aid of one disulphide bond (Figure 1). Various homologues of the TolA protein are known, for example from *E. coli* (SwissProt Acc. No. P19934), *Salmonella* species (for example Genbank Acc. Nos gi16764117 and gi1675986), *Pectobacterium* species (for example Genbank Acc. No. gi16116636) and *Haemophilus* species (for example Genbank Acc. No. gi2126342).

The present inventors have found that the TolAIII domain has remarkable properties which are of particular use as a fusion protein partner to achieve high levels of expression in a host cell.

According to the present invention there is provided a fusion polypeptide for expression in a host cell comprising a TolAIII domain or a functional homologue, fragment, or derivative thereof and a non-TolA polypeptide excluding a polypeptide consisting of or comprising an amino acid sequence corresponding to residues 1-86 of mature phage minor coat gene 3 protein g3p..

Lubkowski *et al.* (1999; *supra*) disclose a fusion protein comprising residues 1-86 (the N1 domain) of the filamentous Ff bacteriophage minor coat gene 3 protein g3p towards the N-terminus and residues 295-425 (which include the TolAIII domain) of TolA, a coreceptor of g3p, towards the C-terminus, and a C-terminal Ala₃His₆ tail. The fusion protein was used by Lubkowski *et al.* to elucidate the crystal structure of a complex formed between the g3p N1 and TolAIII domains.

Further provided according to the present invention is a fusion polypeptide for expression in a host cell comprising a TolAIII domain or a functional homologue, fragment, or derivative thereof and a non-TolA polypeptide, wherein the TolAIII domain or functional homologue, fragment, or derivative thereof is located towards the N-terminus of the fusion polypeptide and the non-TolA polypeptide is located towards the C-terminus of the fusion polypeptide.

Alternatively, the TolAIII domain or functional homologue, fragment, or derivative thereof may be located towards the C-terminus of the fusion polypeptide and the non-TolA polypeptide excluding a polypeptide consisting of an amino acid sequence corresponding to residues 1-86 of mature phage minor coat gene 3 protein g3p may be located towards the N-terminus of the fusion polypeptide.

As used herein, the terms "polypeptide" and "protein" are synonymous and refer to a sequence of two or more linked amino acid residues.

The TolAIII domain has been shown by the present inventors to facilitate higher than expected levels of TolAIII fusion polypeptide expression in a host cell. The TolAIII domain fusions will be useful, for example, for obtaining purified protein and polypeptide partners and/or for studying the properties of these partners.

The TolAIII domain or functional homologue, fragment, or derivative thereof may be codon-optimised for expression in the host cell.

The fusion polypeptide may further comprise a linker between the TolAIII domain or functional homologue, fragment, or derivative thereof and the non-TolA polypeptide. The linker may provide a physical separation between the TolAIII domain or functional homologue, fragment, or derivative thereof and the non-TolA polypeptide or may be functional. The linker may comprise at least one cleavage site for an endopeptidase. For example, the cleavage site may comprise the amino acid sequence DDDDK and/or LVPR and/or IEGR.

In one embodiment, the fusion polypeptide according to invention may further comprise an affinity purification tag. The affinity purification tag may be located at the N-terminus of the fusion polypeptide. For example, the affinity purification tag is an N-terminal His_n tag, with n=4, 5, 6, 7, 8, 9 or 10 (preferably 6), optionally with the His_n tag linked to the fusion polypeptide by one or more Ser residues (preferably 2). The affinity purification tag will provide one means for immobilising the fusion polypeptide, for example as a step in purification.

Preferrably, the TolAIII domain consists of amino acid residues 329-421 of *Escherichia coli* TolA sequence (SwissProt Acc. No. P19934).

The host cell may be bacterial (for example, *Escherichia coli*).

Further provided according to the present invention is a DNA molecule encoding the fusion polypeptide as defined above. The mRNA properties of the DNA molecule when transcribed may be optimised for expression in the host cell.

Also provided is an expression vector comprising the DNA molecule as defined above for expression of the fusion polypeptide of the invention. The expression vector may have an inducible promoter (for example, the IPTG-inducible T7 promotor) which drives expression of the fusion polypeptide. The expression vector may also have an antibiotic resistance marker (for example, the *bla* gene, which confers resistance to ampicillin and chloramphenicol).

In another aspect of the invention there is provided a cloning vector for producing the expression vector as defined above, comprising DNA encoding the TolAIII domain or a functional homologue, fragment, or derivative thereof upstream or downstream from a cloning site which allows in-frame insertion of DNA encoding a non-TolA polypeptide. The cloning vector may further comprise DNA encoding at least one cleavage site (for example, the amino acid sequence DDDDK and/or LVPR and/or IEGR) for an endopeptidase, the cleavage site located between the DNA encoding the TolAIII domain or a functional homologue, fragment, or derivative thereof and the cloning site. The cloning site may comprise at least one restriction endonuclease (for example, *Bam*HI and/or *Kpn*I) target sequence. The cloning vector may further comprise DNA encoding an affinity purification tag as defined above. The cloning vector may further comprise an inducible promoter (for example, the IPTG-inducible T7 promotor) and/or DNA encoding an antibiotic resistance marker (for example, the *bla* gene, which confers resistance to ampicillin and chloramphenicol).

For example, the cloning vector may structure of pTolE, pTolT or pTolX (as shown in Figure 2 with reference to the description).

Also provided is the use of the TolAIII domain or functional homologue, fragment, or derivative thereof for production of a fusion polypeptide as defined above.

Further provided is the use of the TolAIII domain or functional homologue, fragment, or derivative thereof for production of the DNA molecule as defined above.

Yet further provided is the use of the TolAIII domain or functional homologue, fragment, or derivative thereof for production of an expression vector as defined above.

Also provided is the use of the TolAIII domain or functional homologue, fragment, or derivative thereof for production of a cloning vector as defined above.

In one aspect there is provided a host cell containing the DNA as defined above and/or the expression vector as defined above and/or the cloning vector as defined above.

In another aspect there is provided the use of the fusion polypeptide as defined above for immobilisation of the non-TolA polypeptide, comprising the step of:

binding the fusion polypeptide to a TolA binding polypeptide (eg. the TolA-recognition site of colicin N [Gokce *et al.*, 2000, *supra*] or other colicins, the TolA binding region of bacteriophage g3p-D1 protein [Riechmann & Holliger, 1997, *Cell* 90: 351-360], or the TolA binding region of TolB or other Tol proteins).

It is known that TolAIII interacts specifically with several naturally occurring proteins such as colicins, phage proteins and other Tol proteins. This range of existing binding partners makes the over expression of TolAIII fusion proteins of particular utility since these proteins may be used in purification or immobilisation technologies. The TolAIII domain therefore not only drives high expression of the fusion polypeptide but also provides an affinity tag for purification, immobilisation or analysis of the fusion polypeptide. The TolAIII binding proteins (or binding polypeptide domains thereof) could be used to provide binding sites for the TolAIII fusions (as in Figure 6). Protein chips could be made using these TolAIII proteins which then bind the TolAIII fusion proteins. This provides a way to immobilise a wide variety of proteins on the surface using the TolAIII fusion as the common interaction.

Alternatively, the fusion polypeptide comprising an affinity tag as defined above may be used for immobilisation of the non-TolA polypeptide, comprising the step of:
binding the affinity tag of the fusion polypeptide to a binding moiety.

Also provided is the use of the fusion polypeptide as defined above for purification and isolation of the non-TolA polypeptide, comprising the steps of:

binding the fusion polypeptide to a TolA binding polypeptide (eg. the TolA-recognition site of colicin N or other colicins, the TolA binding region of bacteriophage g3p-D1 protein, or the TolA binding region of TolB or other Tol proteins);

cleaving the non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof using an endopeptidase; and

separating the cleaved non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof.

In an alternative embodiment, the fusion polypeptide comprising an affinity tag may be used for purification and isolation of the non-TolA polypeptide, comprising the steps of:

binding the affinity tag of the fusion polypeptide to a binding moiety;

cleaving the non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof using an endopeptidase; and

separating the cleaved non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof.

The fusion polypeptide as disclosed herein may be used for studying interaction properties of the non-TolA polypeptide or the fusion polypeptide, for example self-interaction, interaction with another molecule, or interaction with a physical stimulus.

Also provided is a method for high expression of a polypeptide as a fusion polypeptide in a host cell, comprising the step of expressing the polypeptide as a fusion polypeptide as defined above in a host cell. Levels of expression of a polypeptide as a fusion protein defined herein will be high relative to levels of expression of a polypeptide not linked to the TolAIII domain.

The invention will be further described with reference to the accompanying figures. Of the figures:

Figure 1: (Prior art) Shows the structure and sequence of third domain of TolA. The model is from the crystal structure of complex between TolAIII and N1 domain of minor coat gene 3 protein from filamentous bacteriophage (Holliger *et al.*, 1999, *supra*). Disulphide bond is labelled black. Residues 333-421 were resolved in the model. Below is the sequence of the TolAIII domain used in the present study (amino acids 324-421 of TolA protein; TolA protein sequence from SwissProt Acc. No. P19934).

Figure 2: Shows pTol expression vectors. pTol vectors are T7 based expression vectors derived from pET8c. The TolAIII with tags, depicted in the middle panel, is inserted in between XhoI and MluI sites. His₆-Ser₂ linker precedes gene for domain III, coding for amino acids 329-421 of TolA (middle panel). Short flexible part (Gly-Gly-Gly-Ser) then follows and the cleavage site for endopeptidases composed of four or five amino acids (denoted by X in middle panel and underlined in bottom panel). The cleavage site is denoted by an arrow. Stop codons are shown as asterisks.

Figure 3: Characterization of TolAIII expression. A: SDS-PAGE of expressed TolAIII from using three different vectors. Lane 1, pTolT uninduced; lane 2, pTolX; lane 3, pTolE; lane 4, pTolT. B: Growth curve of bacteria with pTolT. Uninduced (solid squares) sample, induced (open squares) sample. 1 mM IPTG was added to induce sample at the time denoted by an arrow. C: SDS-PAGE of fractionation of bacteria after expression of TolAIII from pTolT. Lane 1, uninduced sample; lane 2, induced bacteria; lane 3, periplasmic fraction; lane 4, cytoplasmic fraction; lane 5, insoluble (membrane + inclusion bodies) fraction. M, molecular weight marker.

Figure 4: Expression of different proteins in E.coli using pTol system. A: Expression of fusion of TolAIII with prokaryotic proteins. Lane 1, colicin N 40-76; lane 2, Δ10 T-domain colicin N; lane 3, R-domain colicin N. Bottom panel presents an estimation of proportion of expressed protein in bacterial cells as determined from scanned gels with Tina. Values

reported represent average of estimation from 5-11 colonies \pm SD. B: Expression of fusion of TolAIII with eukaryotic proteins. Lane 1, PDK2; lane 2, NBD1 domain; lane 3, EqtII; lane 4, PLA₂. Values in bottom are average of estimation from 4-8 colonies \pm SD. C: Expression of fusion of TolAIII with membrane proteins. Lane 1, uninduced pTolT; lane 2, induced BcrC; lane 3, induced TM1. The position where expressed BcrC and TM1 should appear on the gel is denoted by an asterisk and circle, respectively. M, molecular weight marker; C, control of bacterial cells from uninduced sample of pTolT.

Figure 5: Purification of R-domain of colicin N. Lane 1, uninduced cells containing pTolT-Rdomain vector; lane 2, induced cells; lane 3, bacterial cytoplasmic fraction; lane 4, flowthrough of Ni-NTA chromatography; lane 5, purified fusion TolT-Rdomain proteins; lane 6, purified R domain after cleavage and ion-exchange chromatography.

Figure 6: Depicts diagrammatically various uses of a His-tagged fusion protein. A TolIIIA ("Tol") fusion partner with a His₆ affinity tag is attached to a non-TolAIII polypeptide (depicted as a circle). The non-TolAIII polypeptide may be removed from the fusion protein by endopeptidase cleavage (depicted as a lightning bolt) and purified. The fusion protein may be immobilised to a Nickel Chelate substrate via the His₆ tag or (as shown) using an immobilised tag made from all or part of a recognised TolAIII binding protein from bacteria or phage, allowing the non-TolAIII polypeptide (or the entire fusion) to be available for interaction studies.

EXPERIMENTAL

In our laboratory we first prepared fusion proteins between domain III of periplasmic TolA protein (TolAIII) and T domain of colicin N. Huge amounts of fusion protein was isolated when TolAIII was at the N-terminus and T-domain at the C-terminus. On the other hand, when colicin N was the N-terminal partner no expression of fusion protein was obtained. Although having TolAIII as an N-terminal partner was preferred in the fusion protein with the Tdomain of colicin N, it is possible that TolAIII could be useful as either a N or C-terminal partner in a fusion protein with other proteins.

Here we describe cloning of pTol vectors that use TolAIII as a fusion partner at the N-terminal part of expressed fusion protein. We show that levels of expression of various fusion proteins are around 20 % of total bacterial proteins and we were able to purify 50-90 mg of fusions per l of bacterial broth. We prepared different components of colicin N by the use of this system.

Several proteins have been expressed using the system. These were different parts and domains of colicin N (TolA binding box (peptide of amino acids 40-76), deletion mutant of T-domain ($\Delta 10$) and R domain), representing prokaryotic proteins. Human phospholipase A₂, pore-forming protein from sea anemone equinatoxin II, nucleotide binding domain 1 (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) and human mitochondrial pyruvate dehydrogenase kinase 2 (PDK2) were examples of eukaryotic proteins. Transmembrane proteins were represented by BcrC, a component of bacitracin resistance system from *B. licheniformis*, and transmembrane domain 1 (TM1) of human CFTR.

In all cases except for two membrane proteins the yields of fusion protein were higher than the individual proteins. The expression of small peptides and soluble proteins was consistently good. More difficult targets were also chosen. The membrane proteins did not express at all. The human PLA, PDK₂ and equinatoxin expressed well but as in the case of the individual proteins much ends up as insoluble fraction. PLA has many SS bonds and PDK has consistently resisted soluble expression in other systems. The TolAIII was not able to

overcome the insoluble behaviour of these fusion partners but their recovery from inclusion bodies is still possible.

MATERIALS AND METHODS

Cloning of pTol vectors:

The original vector used in cloning was a derivative of pET3c (Novagen) termed pET8c. The pET8c vector was constructed by adding to the pET3c vector nucleotides encoding methionine followed by six histidine and two serine residues downstream of the cloning site (Politou, A.S. *et al.*, 1994, *Biochemistry* **33**(15): 4730-4737). The pET8c vector was used for an expression of fusion between domain III of TolA (amino acids 329-421; SwissProt Acc. No. P19934) protein and T domain of colicin N. It is T7 based expression vector with *bla* gene, providing ampicillin selection. The fusion protein contains a methionine followed by six histidines and two serines at the N-terminal part. This linker enables easy purification using Ni-chelate affinity chromatography. The fusion partners were linked together via *Bam*HI site. The C-terminal end of the fusion was cloned via *Mlu*I site. The T-domain gene was removed from the vector by restricting it with *Bam*HI and *Mlu*I. An adaptor sequence was then ligated into the vector. It was composed in such a way that it removed the *Bam*HI site within the flexible linker, but introduced a new *Bam*HI site just after the cleavage sequence for endopeptidases (Figure 2). In this way fused partners can be cloned in pTol vector via *Bam*HI or *Kpn*I site, leaving tag of two (Gly-Ser) or four (Gly-Ser-Gly-Thr) amino acids, respectively, at the N-terminus (see Figure 2). Linker between TolAIII and fused partner is, therefore, composed of flexible part (Gly-Gly-Gly-Ser) and cleavage sequence for endopeptidases (enterokinase, factor Xa or thrombin) (Figure 2). The oligonucleotides (all oligonucleotides were from MWG Biotech) with the following sequences were used as an adaptors:

E(+) (5'-GATCTGATGATGACGATAAAGGATCCGGTACCTGATGAA-3') and
E(-) (5'-CGCGTTCATCAGGTACCGGATCCTTTATCGTCATCATCA-3') for
enterokinase,
X(+) (5'-GATCTATTGAAGGTCGCGGATCCGGTACCTGATGAA-3') and
X(-) (5'-CGCGTTCATCAGGTACCGGATCCGCGACCTTCAATA-3') for factor Xa, and
T(+) (5'-GATCTCTGGTTCCGCGCGGATCCGGTACCTGATGAA-3') and T(-) (5'-
CGCGTTCATCAGGTACCGGATCCGCGCGGAACCAGA-3') for thrombin cleavage sites.

Newly cloned vectors were named pTolE, pTolX, pTolT and they comprise cleavage sequences for enterokinase, factor Xa, and thrombin, respectively. Fusion partners used to test the system were cloned into the pTol vectors via *Bam*HI and *Mlu*I sites. If the nucleic acid sequence coding for a particular protein contained internal *Bam*HI site, a *Kpn*I site was used instead. Nine different proteins were used to test the system (Table 1). Coding sequences were amplified by PCR. Reaction mixture contained (in 100 µl total volume): 10 µl of 10 X reaction buffer supplied by the producer, 2 µl of 100 mM MgSO₄, 4 µl of dNTP mix (200 µM final concentration), 100 pmol of each oligonucleotide, approximately 20 ng of target DNA and 1 Unit of Vent DNA polymerase (New England BioLabs). Typically the following cycles were used: 10 min at 97°C; 30 cycles, each composed of 2 min denaturation at 97°C, 1 min of annealing at 58°C, 1 min of extension at 72°C; 7 min at 72°C and soak at 10°C. PCR fragments were purified using commercial kits (Qiagen) and restricted by an appropriate restriction endonucleases. Restricted fragments were cloned into pre-cleaved pTol vector. The correct nucleotide sequence of the fusion protein was verified by sequencing.

Table 1: Proteins used to test pTol fusion expression system:

| Protein | Amino acids / SwissProt Acc. No. | Mw ^a | Plasmid | Cloning ^b Site | Oligos for PCR |
|---------------------------|-------------------------------------|-----------------|-------------|------------------------------|-------------------|
| Colicin N 40-76 | 40-76 / P08083 | 16038 | pTolE, T, X | <i>Bam</i> HI | 1,2 |
| Colicin N Δ10 T-domain | 11-90 / P08083 | 18567 | pTolT | <i>Bam</i> HI | 3,4 |
| Colicin N R domain | 67-183 / P08083 | 24667 | pTolT | <i>Bam</i> HI | 5,6 |
| Human PLA ₂ | 21-144 / NP_000291.1 ^c | 25810 | pTolT | <i>Kpn</i> I | 7,8 |
| Equinatoxin II | 36-214 / P17723 | 31575 | pTolE | <i>Bam</i> HI | 9,10 |
| NBD1 domain of human CFTR | 460-650 / P13659 | 33134 | pTolT | <i>Bam</i> HI | 11,12 |
| Human PDK2 | 18-407 / Q15119 | 56193 | pTolT | <i>Kpn</i> I | 13,14 |
| BcrC | 2-203 / P42334 | 34775 | pTolT | <i>Bam</i> HI | 15,16 |
| TM1 domain of human CFTR | 2-355 / P13659 | 52590 | pTolT | <i>Bam</i> HI | 17,18 |

^a Mw of fusion protein calculated from the sequence. ^b Restriction site used for cloning at the N-terminal part of the fusion protein. In all cases C-terminal site used was *Mlu*I. ^c RefSeq accession number.

Oligonucleotides to amplify the desired proteins were of the following sequences (all 5'-3'; see also Table 1):

1. TTTTGGATCCAATTCCAATGGATGGTCATGGAG

2. AAGGATCCAAGCTTCAAGGTTTAGGCTTTGAATTATTGTCC
3. TTTTGGATCCAATGCTTTTGGTGGAGGGAAAAATC
4. CTCAGCGGTGGCAGCAGCC
5. CGCGGATCCCATGGGGACAATAATTCAAAGC
6. GGCGAATTCACGCGTTAAAATAATAATTTCTGGCTCAC
7. CCGGGGTACCAATTTGGTGAATTTCCACAGAATGATC
8. GGCGAATTCACGCGTTAGCAACGAGGGGTGCTCCC
9. CGCGGATCCGCAGACGTGGCTGGCGCC
10. GGCGAATTCACGCGTTAAGCTTTGCTCACGTGAGTTTC
11. CGCGGATCCTCTAATGGTGATGACAGCCTC
12. GGCGAATTCACGCGTTAGAAAGAATCACATCCCATGAG
13. CCGGGGTACCAAGTACATAGAGCACTTCAGCAAGTTC
14. GGCGAATTCACGCGTTACGTGACGCGGTACGTGGTTCG
15. CGCGGATCCTTTTCAGAATTAAATATTGATG
16. GGCGAATTCACGCGTTAAAAGTTCTTCGATTTATCG
17. CGCGGATCCCAGAGGTCGCCTCTGG
18. GGCGAATTCACGCGTTAGGGAAATTGCCGAGTGAC

Expression of proteins in E. coli

All proteins were expressed in an *E. coli* BL21(DE3)pLysE strain (from Novagen). The strain was transformed with plasmid and grown on LB plates with appropriate selection (Ampicillin, Chloramphenicol). One colony was used to inoculate 5 ml of LBAC medium (Ampicillin at 100 µg/ml, Chloramphenicol at 34 µg/ml, both from SIGMA). Bacteria were grown on rotating wheel at 37°C. After 60 min the expression of recombinant proteins was induced by an addition of 1 mM (final) IPTG and bacteria were grown for additional 4 h. Small samples (corresponding to a volume of bacteria which when resuspended in 1 ml yields $A_{600}=0.5$) was analysed on SDS-PAGE. Gels were stained with Coomassie and scanned at 600 dpi using commercial scanner. The amount of expressed proteins was estimated from the gels using the program Tina 2.0. For large-scale expression, 5 ml of bacterial culture in stationary phase was used to inoculate 250 ml of LBAC medium and grown at 37°C in orbital shaker at 180 rpm overnight. The next morning 20-25 ml of overnight culture was used to inoculate 500 ml of

M9 LBAC medium. In total 3-5 l of bacterial culture were grown for a single protein. Bacteria were grown at the same conditions until A_{600} reached approximately 0.8. Then the production of recombinant proteins was induced by adding IPTG to final 1 mM concentration. Bacteria were grown for additional 4-5 h, centrifuged for 5 min at 5000 rpm at 4°C, and stored at -20°C.

Isolation of proteins from bacteria

Pelleted bacteria were resuspended (2 ml of buffer / g of cells) in 50 mM NaH_2PO_4 , pH 8.0, 300 mM NaCl, 10 mM imidazole, 20 mM β -mercaptoethanol (buffer A), with following enzymes and inhibitors of proteases (final concentrations): DNase (10 $\mu\text{g/ml}$), RNase (20 $\mu\text{g/ml}$), lysozyme (1 mg/ml of buffer), PMSF (0.5 mM), benzamidine (1mM). They were incubated on ice for an hour and occasionally vigorously shaken. The resuspended bacteria were sonicated for 3 min with a Branson sonicator and then centrifuged in a Beckman ultracentrifuge at 40000 rpm, 4°C in 45ti rotor. Supernatant was removed and placed at 4°C. Pellet was resuspended in the same buffer without enzymes and inhibitors (1 ml / g of weight) and kept on ice for 15 min. Centrifugation at the same conditions followed after additional 1 min of sonication. Supernatants from both centrifugations were merged and applied at approximately 1 ml/min to 1-3 ml of Ni-NTA resin (Qiagen) equilibrated with buffer A. Typically, column with bound protein was washed with two fractions of 3 ml of buffer A, two fractions of buffer A with 20 mM imidazole and 6-10 fractions of buffer A with 300 mM imidazole. Fractions were analysed on SDS-PAGE. Fractions of interest were pooled and dialysed three times against water (5 l) at 4°C. Purity was checked by SDS-PAGE. Proteins were stored at 4°C in 3 mM NaN_3 . Protein concentration was determined by using extinction coefficients calculated from the sequence.

Fractionation of bacterial proteins

All bacterial proteins were fractionated in order to see the amount of insoluble expressed proteins. Pelleted bacteria from 100 ml of broth were resuspended in 40 ml of 20 % sucrose, 1 mM EDTA, 30 mM Tris-HCl, pH 8.0 and incubated 10 min at room temperature. They were centrifuged at 9000 g for 10 min at 4°C. Supernatant was removed and pellet was gently resuspended in 8 ml of ice-cold 5 mM MgSO_4 . Bacteria were gently shaken and incubated on

ice for 10 min. Bacterial protoplasts were centrifuged again at the same conditions. Supernatant was removed as periplasmic fraction. Pellet was resuspended in 10 ml of 20 mM NaH_2PO_4 , pH 8.0, with 1 mg of lysozyme and benzamidine. It was shaken vigorously and incubated on ice for 30 min, and finally, sonicated 5×30 s. Cytoplasmic proteins were removed from insoluble material by centrifugation at 35 000 g at 4°C for 30 min. Supernatant was removed as cytoplasmic fraction and pellet was resuspended in 2 ml of 8 M urea, 10 mM Tris-HCl, pH 7.4, 0.5 % Triton X-100 as insoluble fraction (membrane proteins and putative inclusion bodies).

Cleavage and purification of TolAIII-R-domain colicin N fusion

Pure R-domain of colicin N was produced using the pTol expression system. 45 mg of TolAIII-R-domain was incubated in 35 ml of cleavage mixture at 20°C for 20 h. Cleavage mixture contains buffer as specified by producer and thrombin (Restriction grade, Novagen) at 0.1 U/mg of fused protein. Cleaved products were dialysed three times against 5 l of 40 mM Tris-HCl, pH8.4 at 4°C, each time at least 4 h. Cleaved R domain was separated from TolAIII and uncleaved fusion protein by ion-exchange chromatography on FPLC system (Pharmacia). Proteins were applied to Mono S column (Pharmacia) at 1 ml/min in 40 mM Tris-HCl, pH8.4. After unbound material was washed from the column, R-domain was eluted by applying gradient of NaCl from 0 to 500 mM in the same buffer in 30 min. Large peak at approximately 70% of NaCl (app. 350 mM) was collected and checked for purity by SDS-PAGE.

RESULTS

Expression of TolAIII protein in E. coli

Third domain of TolAIII with tags (Figure 2) was expressed from three different expression vectors (Figure 3), pTolE, pTolT, and pTolX. In each case, the expression of TolAIII was huge, sometimes reaching up to 40 % of all bacterial proteins (see Figure 3A). Specifically, the amount of expressed TolAIII from pTolT was $26.96 \% \pm 1.67$ (n=5). The amount of expressed TolAIII was approximately the same regardless which vector was used. TolA expressed in bacteria did not interfere with normal bacterial metabolism. The growth curve was very similar for induced and non-induced bacteria (Figure 3B). All of the TolAIII protein

was expressed in soluble form. No inclusion bodies were revealed by visual inspection of pelleted remains of bacteria after osmotic lysis, lysozyme treatment, sonication, and centrifugation. Furthermore, none of the TolAIII was found in insoluble cell fraction after fractionation of proteins from bacteria. Insoluble fraction represents membrane proteins and should contain also recombinant proteins in inclusion bodies (Figure 3C). Bacteria containing TolAIII were a bit more fragile than normal. TolAIII was released from the cells already after mild hypo-osmotic treatment, which should release only periplasmic proteins.

Expression of other proteins in E. coli as fusions with TolAIII

Nine proteins were tested in order to check the suitability of pTol expression system for expression and preparation of other proteins (Table 1). These were different parts and domains of colicin N (TolA binding box (peptide of amino acids 40-76), deletion mutant of T-domain ($\Delta 10$) and R domain), representing prokaryotic proteins. Human phospholipase A₂, pore-forming protein from sea anemone equinatoxin II, nucleotide binding domain 1 (NBD1) of human cystic fibrosis transmembrane conductance regulator (CFTR) and human mitochondrial pyruvate dehydrogenase kinase 2 (PDK2) were examples of eukaryotic proteins. Transmembrane proteins were represented by BcrC, a component of bacitracin resistance system from *B. licheniformis*, and transmembrane domain 1 (TM1) of human CFTR. Proteins chosen represent variations in size (app. 4.4 of colicin 40-76 kDa vs. 44 kDa of PDK2), genetic code (prokaryotic vs. eukaryotic proteins), protein location (soluble vs. membrane), and disulphide content (PLA₂, 7 disulphides vs. equinatoxin, none). Fusion proteins were expressed at high proportion in *E. coli* using pTol system (Figure 4). Again, the expression was as high as 40% in some cases, but average was around 20-25 % (see Figure 4B and C bottom panels). The only two exceptions were membrane proteins, BcrC and TM1. In this case a band corresponding to their size was lacking from the gel (Figure 4C). As opposed to expression of TolAIII alone, expression of fusion proteins interferes with the growth of bacteria. In the case of PLA₂ and membrane proteins, TM1 and BcrC, the amount of bacteria at the end of the growth halved in some cases. Interestingly, expression of fusion of PDK2 in bacterial cell had positive effect and there was always slightly more bacteria at the end of the growth (not shown). Some of the bacteria expressing fusions were further fractionated. PDK2 and PLA₂ were expressed as insoluble inclusion bodies. EqtII and R-domain were found

mainly in the insoluble fraction, but some proportion was found also in cytoplasmic fraction (10-25 % of expressed proteins) (not shown).

Isolation and cleavage of fusion proteins

Expressed fusions were isolated from the cytoplasm by simple extraction into buffered solution, which was applied onto Ni-NTA column. By this single step proteins were already more than 95 % pure (Figure 5). Yields of isolated fusions were on average approximately 50 mg/l of bacterial broth, but reached up to 90 mg/l (Table 2). Even proteins, which were mainly expressed as inclusion bodies, were isolated in significant quantities by this procedure, i.e. 11 mg/ml of EqtII fusion was isolated. One of the fusion proteins, TolE-Tdomain 40-76, was used for the preparation of a peptide sample suitable for structure determination by NMR. It was expressed in M9 minimal media containing $^{15}\text{NH}_4\text{Cl}$. Even in minimal media it was possible to express and produce fusion at significant amounts, almost 70 mg of pure fusion was obtained per litre of bacterial culture.

Table 2: Yields of isolated fusion proteins by using pTol system

| Protein ^a | Yield (mg/l bacterial broth) |
|------------------------------------|---------------------------------|
| TolE-Tdomain 40-76 | 46.7 |
| ^{15}N TolE-Tdomain 40-76 | 67.1 |
| TolT-Tdomain 40-76 | 83.8 |
| TolX-Tdomain 40-76 | 89.6 |
| TolT- Δ 10 Tdomain | 37.4 |
| TolT-Rdomain | 51 |
| TolE- EqtII | 11 |
| TolT-PDK | 1.4 |

^a Proteins are named after plasmid used for expression of fusion protein.

Pure R-domain was prepared from TolT-Rdomain fusion by cleavage with thrombin and separation of cleavage products by ion-exchange chromatography. The results of such purification scheme are presented on Figure 5. By the outlined procedure 13 mg of pure functional R domain was prepared from 1 l of starting bacterial culture. Slightly lower yield as expected from the amount of soluble fusion is a consequence of R-domain precipitation during

the preparation. However, yield presented here is still more than two times higher than the system which provides directly expressed R-domain.

DISCUSSION

TolAIII is expressed in huge quantities in soluble form in bacterial cytoplasm. Among the reasons for high expression of proteins in *E. coli* are most commonly cited appropriate codon usage, stability of mRNA transcript, size, content of disulphide bonds, and toxicity to the cell. TolAIII is small protein, with only one disulphide bond. It is very stable and monomeric in solution even at concentrations as high as 30 mg/ml (data from analytical ultracentrifugation and gel filtration, not shown). The small size and tendency not to aggregate are certainly important in tolerance of heterologous material in the cytoplasm of bacteria. A further advantage of TolAIII gene is, that it is bacterial protein and as such it possesses only 5 codons (4.7 % of 106 amino acids excluding protease cleavage site) rarely transcribed in *E. coli* genome. They are scattered along the sequence. An improvement of its expression could be achieved by engineering of the conformation of its mRNA transcript. It was shown that, for a high yield of transcribed RNA, sometimes the conformation of RNA should be such, that the ribosome binding site and start codon should be exposed and not involved in base pairing. In the case of TolAIII mRNA both are involved in building short stems and not always completely exposed (analysis of transcribed RNAs of 60-120 nucleotides (step of 10 nt) by Mfold on <http://bioinfo.math.rpi.edu/~zukerm/>). High expression of TolAIII protein in the T7 based vector and the high yields of pure product are comparable or even better than published and existing systems for production of fusion proteins in *E. coli*.

We have employed a domain of a periplasmic bacterial protein as a fusion partner in the overexpression of various proteins of bacterial and eukaryotic origin. Some small peptides or domains could be attached to TolAIII without significantly changing its size. The same amount of expressed protein would then be expected. In fact, the yield of fusion containing colicin N 40-76 peptide was the same as for TolAIII itself. The system is suitable for the preparation of eukaryotic proteins as well. In particular, the level of expression of EqtII is much more improved over the published one. Approximately 20 % of total expression of the

fusion contrasted with approximately 5 % in the case of direct expression. The majority of EqtII expressed from the pTol system is in the insoluble fraction, but isolation of the soluble cytoplasmic fraction still resulted in a large improvement in yield over the published method. The pTol system might also be applicable for proteins expressed as inclusion bodies. For example, the amount of expressed PLA₂ is similar to other expression systems, however the fusion protein can easily be isolated by Ni-NTA chromatography and then refolded and cleaved on the column matrix. An interesting observation was that the two membrane proteins studied did not express as fusion proteins with pTolA system, although the reason for this is unclear at the moment.

Three expression vectors were constructed providing three different cleavage sites for endopeptidases widely used in molecular biology, *e.g.* enterokinase, factor Xa and thrombin. Recognition sites for endopeptidases differ in amino acid sequence and size. These differences dramatically change properties of the small TolAIII partner in fusion proteins (Table 3). TolAT and TolAX are basic, calculated pI more than 8.5, TolAE is acid in nature, pI of 6.6. This is the result of four aspartates in the recognition sequence for enterokinase (DDDDK). The constructed vectors thus enable higher flexibility, *i.e.* one can easily choose appropriate vector on the basis of the properties of fused partner. In our case, R-domain of colicin N was expressed in pTolT vector since R-domain is even more basic (pI 9.7) than cleaved TolAIII. On the other hand, colicin N peptide 40-76 has almost the same pI as TolAT or TolAX. This make subsequent purification much more difficult, the peaks representing peptide and TolAIII would then overlap in ion-exchange chromatography. Therefore, peptide was expressed in pTolE. Cleaved TolAIII was not bound to the column at chosen conditions and the difference in pI of the uncleaved fusion (pI 7.2) and peptide was large enough to get clearly resolved peaks (not shown).

Table 3: Physical properties of TolAIII proteins after endoproteinase cleavage

| Protein ^a | Amino acids | Mw ^b | pI ^b |
|----------------------|-------------|-----------------|-----------------|
| TolAE | 111 | 11716.1 | 6.57 |
| TolAT | 110 | 11593.2 | 8.93 |
| TolAX | 110 | 11583.1 | 8.57 |

^a Proteins are named according to the vector in which they were produced. ^b Calculated from the sequence.

We could produce functional parts of the colicin N toxin by using the pTol expression system. We produced functional R-domain and 39 residue peptide composed of colicin residues 40-76. His-tagged R-domain expresses poorly and irreproducibly and the tolA fusion expressed consistently well and improved the yield by more than two fold. Peptide was produced as ^{15}N labelled sample for NMR structure determination. Preparation of large quantities of labelled peptide sample for NMR structure analysis can be problematic and a significant financial burden to research groups. High yields and versatility of the pTol system should make preparation of short peptides and proteins much cheaper and alternative to chemical synthesis and other expression systems. The system may be particularly useful for reproducible high level expression of small (<20 kDa) soluble proteins and unstructured peptides. For example, the system might prove useful in the preparation of ^{15}N or ^{13}C labelled small peptides for NMR structural studies.

CLAIMS

1. A fusion polypeptide for expression in a host cell comprising a TolAIII domain or a functional homologue, fragment, or derivative thereof and a non-TolA polypeptide excluding a polypeptide consisting of an amino acid sequence corresponding to residues 1-86 of mature phage minor coat gene 3 protein g3p.
2. A fusion polypeptide for expression in a host cell comprising a TolAIII domain or a functional homologue, fragment, or derivative thereof and a non-TolA polypeptide, wherein the TolAIII domain or functional homologue, fragment, or derivative thereof is located towards the N-terminus of the fusion polypeptide and the non-TolA polypeptide is located towards the C-terminus of the fusion polypeptide.
3. The fusion protein according to claim 1, wherein the TolAIII domain or functional homologue, fragment, or derivative thereof is located towards the C-terminus of the fusion polypeptide and the non-TolA polypeptide is located towards the N-terminus of the fusion polypeptide.
4. The fusion polypeptide according to any one of the preceding claims, wherein the TolAIII domain or functional homologue, fragment, or derivative thereof has been codon-optimised for expression in the host cell.
5. The fusion polypeptide according to any one of the preceding claims, further comprising a linker between the TolAIII domain or functional homologue, fragment, or derivative thereof and the non-TolA polypeptide.
6. The fusion polypeptide according to claim 5, wherein the linker comprises at least one cleavage site for an endopeptidase.
7. The fusion polypeptide according to claim 6, wherein the cleavage site comprises the amino acid sequence DDDDK and/or LVPR and/or IEGR.

8. The fusion polypeptide according to any one of the preceding claims, further comprising an affinity purification tag.
9. The fusion polypeptide according to claim 8, wherein the affinity purification tag is located at the N-terminus of the fusion polypeptide.
10. The fusion polypeptide according to claim 9, wherein the affinity purification tag is an N-terminal His_n tag, with n=4, 5, 6, 7, 8, 9 or 10 (preferably 6), optionally with the His_n tag linked to the fusion polypeptide by one or more Ser residues (preferably 2).
11. The fusion polypeptide according to any one of the preceding claims, wherein the TolAIII domain consists of amino acid residues 329-421 of *Escherichia coli* TolA sequence (SwissProt Acc. No. P19934).
12. The fusion polypeptide according to any one of the preceding claims, wherein the host cell is bacterial (for example, *Escherichia coli*).
13. A DNA molecule encoding the fusion polypeptide as defined in any one of claims 1-12.
14. A DNA molecule according to claim 13, wherein the mRNA properties of the DNA molecule when transcribed are optimised for expression in the host cell.
15. An expression vector comprising the DNA molecule according to either one of claim 13 or claim 14 for expression of the fusion polypeptide defined in any one of claims 1-12.
16. The expression vector according to claim 15, having an inducible promoter (for example, the IPTG-inducible T7 promotor) which drives expression of the fusion polypeptide.
17. The expression vector according to either one of claim 15 or claim 16, having an antibiotic resistance marker (for example, the *bla* gene, which confers resistance to ampicillin and chloramphenicol).

18. A cloning vector for producing the expression vector defined in any one of claims 15-17, comprising DNA encoding the TolAIII domain or a functional homologue, fragment, or derivative thereof upstream or downstream from a cloning site which allows in-frame insertion of DNA encoding a non-TolA polypeptide.

19. The cloning vector according to claim 18, further comprising DNA encoding at least one cleavage site (for example, the amino acid sequence DDDDK and/or LVPR and/or IEGR) for an endopeptidase, the cleavage site located between the DNA encoding the TolAIII domain or a functional homologue, fragment, or derivative thereof and the cloning site.

20. The cloning vector according to either one of claims 18 or 19, wherein the cloning site comprises at least one restriction endonuclease (for example, *Bam*HI and/or *Kpn*I) target sequence.

21. The cloning vector according to any one of claims 18-20, further comprising DNA encoding an affinity purification tag as defined in either one of claim 8 or claim 9.

22. The cloning vector according to any one of claims 18-21, further comprising an inducible promoter (for example, the IPTG-inducible T7 promotor).

23. The cloning vector according to any one of claims 18-22, further comprising DNA encoding an antibiotic resistance marker (for example, the *bla* gene, which confers resistance to ampicillin and chloramphenicol).

24. The cloning vector according to any one of claims 18-23, having the structure of pTolE, pTolT or pTolX (as shown in Figure 2 with reference to the description).

25. Use of the TolAIII domain or functional homologue, fragment, or derivative thereof for production of a fusion polypeptide as defined in any one of claims 1-12.

26. Use of the TolAIII domain or functional homologue, fragment, or derivative thereof for production of the DNA molecule as defined in either one of claim 13 or claim 14.

27. Use of the TolAIII domain or functional homologue, fragment, or derivative thereof for production of an expression vector as defined in any one of claims 15-17.

28. Use of the TolAIII domain or functional homologue, fragment, or derivative thereof for production of a cloning vector as defined in any one of claims 18-24.

29. A host cell containing the DNA as defined in claim 12 and/or the expression vector as defined in any one of claims 15-17 and/or the cloning vector as defined in any one of claims 18-24.

30. Use of the fusion polypeptide as defined in any one of claims 5-12 for immobilisation of the non-TolA polypeptide, comprising the step of:

binding the fusion polypeptide to a TolA binding polypeptide (eg. the TolA-recognition site of colicin N or other colicins, the TolA binding region of bacteriophage g3p-D1 protein, or the TolA binding region of TolB or other Tol proteins).

31. Use of the fusion polypeptide as defined in any one of claims 8-12 for immobilisation of the non-TolA polypeptide, comprising the step of:

binding the affinity tag of the fusion polypeptide to a binding moiety.

32. Use of the fusion polypeptide as defined in any one of claims 5-12 for purification and isolation of the non-TolA polypeptide, comprising the steps of:

binding the fusion polypeptide to a TolA binding polypeptide (eg. the TolA-recognition site of colicin N or other colicins, the TolA binding region of bacteriophage g3p-D1 protein, or the TolA binding region of TolB or other Tol proteins);

cleaving the non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof using an endopeptidase; and

separating the cleaved non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof.

33. Use of the fusion polypeptide as defined in any one of claims 8-12 for purification and isolation of the non-TolA polypeptide, comprising the steps of:


binding the affinity tag of the fusion polypeptide to a binding moiety;

cleaving the non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof using an endopeptidase; and

separating the cleaved non-TolA polypeptide from the TolAIII domain or functional homologue, fragment, or derivative thereof.

34. Use of the fusion polypeptide as defined in any one of claims 1-12 for studying interaction properties of the non-TolA polypeptide or the fusion polypeptide, for example self-interaction, interaction with another molecule, or interaction with a physical stimulus.

35. A method for high expression of a polypeptide as a fusion polypeptide in a host cell, comprising the step of expressing the polypeptide as a fusion polypeptide as defined in any one of claims 1-12 in a host cell.



*GSGNTKNN GASGADINNY AGQIKSAIES KFYDASSYAG KTCTLRIKLA EGGDPALCQA
ALAAAKLAKI PKPPSQAVYE VFKNAPLDFK P*

Figure 1(Prior Art)




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.